Allspring Global Investments Holdings LLC Sells 1,080 Shares of Moderna, Inc. (NASDAQ:MRNA)

Allspring Global Investments Holdings LLC reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 5.8% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 17,509 shares of the company’s stock after selling 1,080 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Moderna were worth $1,170,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Moderna by 15.1% in the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after buying an additional 5,129,800 shares during the last quarter. Capital World Investors increased its stake in shares of Moderna by 0.5% in the first quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after acquiring an additional 18,728 shares during the period. Mawer Investment Management Ltd. grew its position in Moderna by 6.7% during the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock worth $204,230,000 after purchasing an additional 120,621 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Moderna by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock valued at $169,542,000 after acquiring an additional 29,566 shares during the period. Finally, Nikko Asset Management Americas Inc. boosted its holdings in Moderna by 156.9% during the first quarter. Nikko Asset Management Americas Inc. now owns 741,783 shares of the company’s stock worth $79,044,000 after buying an additional 453,004 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity

In other news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,184 shares of company stock worth $238,531. Company insiders own 15.70% of the company’s stock.

Moderna Stock Down 0.7 %

Moderna stock opened at $54.36 on Friday. Moderna, Inc. has a one year low of $52.26 and a one year high of $170.47. The stock has a market cap of $20.83 billion, a PE ratio of -3.47 and a beta of 1.66. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock has a fifty day moving average of $65.70 and a 200 day moving average of $101.69.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The company had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same period in the previous year, the firm posted ($3.62) earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post -9.88 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Deutsche Bank Aktiengesellschaft upgraded Moderna from a “sell” rating to a “hold” rating and cut their price objective for the company from $85.00 to $80.00 in a report on Wednesday, August 7th. Leerink Partners cut their price target on Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Piper Sandler decreased their price objective on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. The Goldman Sachs Group reduced their price target on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a report on Monday, September 16th. Finally, TD Cowen dropped their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $94.65.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.